Quyen Luu, MD
Infectious Disease · Macon, GANPI 1558347427
Payments from drug & device makers
Across 667 payments — averaging $1088.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$548K
- Eli Lilly$132K
- ADMA Biomanufacturing LLC$33K
- Paratek Pharmaceuticals, Inc.$2K
- Gilead$920
- Organogenesis Inc.$748
- plus $8K from 42 others
Across 28 payments — averaging $1468.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$21K
- ADMA Biomanufacturing LLC$20K
What the payments were for
- Consulting fees$190%
- Speaking & faculty fees$1,89015%
- Travel & lodging$3223%
- Food & beverage$9,73079%
- Education$4143%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUZYRA$2,365
- Kerecis Omega3 SurgiClose$1,399
- Kerecis Omega3 Marigen$1,094
- Kerecis Omega3 GraftGuide$623
- Vibativ$280
- CUTAQUIG$193
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$193
- Affinity$136
- InnovaMatrix AC$136
- SIMPLIMAX$132
- FLEXITOUCH$124
- ACTITOUCH$124
- ENTRE$124
- Rezzayo$124
- Biktarvy$115
- Puraply Antimicrobial$112
- PuraPly$110
- Fetroja$106
- CRESEMBA$106
How this compares
$725,780 in reported general payments places this provider in the 90th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 80 | $409,767 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $181,296 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 11 | $102,827 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 32 | $83,072 |
| Daptomycin | 139 | $74,619 |
| XolairOmalizumab | 13 | $66,112 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 11 | $47,674 |
| SantylCollagenase Clostridium Hist. | 37 | $13,105 |
| Meropenem | 38 | $9,772 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 27 | $5,879 |
| Entecavir | 15 | $5,116 |
| Cefepime Hcl | 21 | $3,902 |
| Methenamine Hippurate | 43 | $3,031 |
| Sodium Chloride0.9 % Sodium Chloride | 28 | $2,586 |
| Amikacin Sulfate | 16 | $1,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $920 | $409,76780 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $547,911 | $181,29617 claims |
| CSL BehringPrivigen | $91 | $102,82711 claims |
| Grifols USA, LLCGamunex-C | $47 | $83,07232 claims |
| Viiv Healthcare CompanyTriumeq | $413 | $47,67411 claims |
| Smith+NephewSantyl | $191 | $13,10537 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $14 | $2,58628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 260 infectious disease providers in Georgia.
Other infectious disease in Macon
- Harold KatnerMacon$1.3M
- Jeffrey StephensMacon$1M
- Jennifer HoffmanMacon$25K
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Andrew DoldDacula$1.1M
- Jose VazquezAugusta$967K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.